BioCryst Pharmaceuticals, Inc. (BCRX)
10.18
+0.26
(+2.57%)
USD |
NASDAQ |
Sep 02, 16:00
10.02
-0.16
(-1.52%)
After-Hours: 19:41
BioCryst Pharmaceuticals Research and Development Expense (TTM) : 195.46M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 195.46M |
| March 31, 2026 | 187.06M |
| December 31, 2025 | 164.74M |
| September 30, 2025 | 173.40M |
| June 30, 2025 | 169.90M |
| March 31, 2025 | 164.14M |
| December 31, 2024 | 173.39M |
| September 30, 2024 | 193.89M |
| June 30, 2024 | 199.58M |
| March 31, 2024 | 213.12M |
| December 31, 2023 | 214.91M |
| September 30, 2023 | 218.09M |
| June 30, 2023 | 223.98M |
| March 31, 2023 | 234.80M |
| December 31, 2022 | 251.86M |
| September 30, 2022 | 242.41M |
| June 30, 2022 | 239.80M |
| March 31, 2022 | 230.82M |
| December 31, 2021 | 208.03M |
| September 30, 2021 | 180.03M |
| June 30, 2021 | 160.53M |
| March 31, 2021 | 135.35M |
| December 31, 2020 | 122.96M |
| September 30, 2020 | 114.38M |
| June 30, 2020 | 109.26M |
| Date | Value |
|---|---|
| March 31, 2020 | 109.44M |
| December 31, 2019 | 107.07M |
| September 30, 2019 | 103.72M |
| June 30, 2019 | 100.61M |
| March 31, 2019 | 93.94M |
| December 31, 2018 | 84.89M |
| September 30, 2018 | 78.38M |
| June 30, 2018 | 73.88M |
| March 31, 2018 | 68.63M |
| December 31, 2017 | 66.96M |
| September 30, 2017 | 62.20M |
| June 30, 2017 | 58.79M |
| March 31, 2017 | 57.20M |
| December 31, 2016 | 61.01M |
| September 30, 2016 | 67.90M |
| June 30, 2016 | 73.86M |
| March 31, 2016 | 76.22M |
| December 31, 2015 | 72.76M |
| September 30, 2015 | 72.22M |
| June 30, 2015 | 65.19M |
| March 31, 2015 | 59.73M |
| December 31, 2014 | 51.80M |
| September 30, 2014 | 48.90M |
| June 30, 2014 | 43.84M |
| March 31, 2014 | 44.50M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Amgen, Inc. | 7.638B |
| Vertex Pharmaceuticals, Inc. | 3.907B |
| Agenus, Inc. | 57.69M |
| Anika Therapeutics, Inc. | 27.45M |
| Imunon, Inc. | 8.191M |